MCRB Seres Therapeutics Inc - marketcomposite.com

MCRB - Seres Therapeutics Inc8:00:00 PM 4/23/2024

Price

$0.76

+ 0.14 (21.68%)

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Topics

30d

Biotechnology1.00%

Peers

30d

AGIO5.30%

XNCR0.90%

leak data

Stock news

MCRB

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT04-09-2024 11:00:00 AM

CAMBRIDGE, Mass., April 09, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting b

MCRB

Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now03-28-2024 16:47:26 PM

Key Insights Seres Therapeutics' Annual General Meeting to take place on 4th of April CEO Eric Shaff's total...

MCRB

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)03-28-2024 11:00:00 AM

CAMBRIDGE, Mass., March 28, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 700,000 shares of its common stock to Marella Thorell, the Company’s new Executive Vice President and Chief Financial Officer, consisting entirely of stock options.

MCRB

11 Oversold NASDAQ Stocks To Buy Right Now03-13-2024 19:32:20 PM

In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now. NASDAQ Leads The Market On March 12, the Nasdaq Composite Index was […]

MCRB

11 Oversold Healthcare Stocks To Buy Right Now03-13-2024 12:17:14 PM

In this article, we will be taking a look at 11 oversold healthcare stocks to buy right now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Oversold Healthcare Stocks To Buy Right Now. The Healthcare Sector: The New 2024 Idea? The healthcare sector has been popular […]

MCRB

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript03-07-2024 16:48:28 PM

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript March 5, 2024 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were $-0.4. MCRB isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good morning. My […]

MCRB

Q4 2023 Seres Therapeutics Inc Earnings Call03-06-2024 07:17:17 AM

Q4 2023 Seres Therapeutics Inc Earnings Call

MCRB

Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 202303-05-2024 12:32:55 PM

Full Year and Q4 Earnings Highlight VOWST Commercial Success and Restructuring Benefits

MCRB

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates03-05-2024 12:00:00 PM

CAMBRIDGE, Mass., March 05, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.

MCRB

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 202402-28-2024 12:00:00 PM

CAMBRIDGE, Mass., February 28, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update.